Tvardi Therapeutics Ownership | Who Owns Tvardi Therapeutics?


OverviewForecastChart

Tvardi Therapeutics Ownership Summary


Tvardi Therapeutics is owned by 19.53% institutional investors, 27.53% insiders, and 52.94% retail investors. Slate path capital lp is the largest institutional shareholder, holding 9.49% of TVRD shares.

TVRD Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTvardi Therapeutics19.53%27.53%52.94%
SectorHealthcare Stocks 232.80%10.63%-143.43%
IndustryBiotech Stocks 379.48%10.37%-289.85%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Slate path capital lp704.12K9.49%$2.24M
Blackrock funding, inc. /de388.07K5.23%$1.23M
Vanguard group424.82K4.53%$1.83M
American financial group223.66K3.01%$711.24K
Geode capital management182.34K2.46%$579.96K
683 capital management176.03K2.13%$6.77M
Vestal point capital, lp167.00K2.03%$6.51M
Silvercrest asset management group101.03K1.36%$321.29K
State street97.23K1.31%$309.19K
Renaissance92.10K1.24%$292.88K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
683 capital management176.03K0.35%$6.77M
Vestal point capital, lp167.00K0.29%$6.51M
Parkman healthcare partners65.00K0.26%$2.53M
American financial group223.66K0.26%$711.24K
Duncan williams asset management63.24K0.06%$201.11K
Slate path capital lp704.12K0.03%$2.24M
Diadema partners lp2.19K0.02%$85.15K
Persistent asset partners500.000.01%$19.48K
Boothbay fund management20.19K0.01%$786.76K
Schonfeld strategic advisors19.13K0.00%$745.57K

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp167.00K0.29%167.00K
Invesco82.61K0.00%82.61K
Parkman healthcare partners65.00K0.26%65.00K
Vanguard fiduciary trust46.87K-46.87K
Aqr capital management42.19K0.00%42.19K

Top Sellers

HolderShares% AssetsChange
Jane street group---47.44K
Marshall wace, llp---24.98K
Farallon capital management21.44K0.00%-21.79K
Quadrature capital---20.96K
Squarepoint ops32.68K0.00%-19.11K

New Positions

HolderShares% AssetsChangeValue
Vestal point capital, lp167.00K0.29%167.00K$6.51M
Invesco82.61K0.00%82.61K$3.22M
Parkman healthcare partners65.00K0.26%65.00K$2.53M
Vanguard fiduciary trust46.87K-46.87K$149.05K
Aqr capital management42.19K0.00%42.19K$134.17K

Sold Out

HolderChange
Cornerstone planning group-1.00
Trust co of toledo na /oh/-9.00
Kiker wealth management-13.00
Raymond james financial-65.00
Amalgamated bank-169.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202548-28.36%1,830,953-29.68%191.96%33-26.67%4-33.33%
Sep 30, 202537-22.92%1,220,244-36.55%143.50%27-43.75%3-
Jun 30, 202530-897,987-9-30---

Insider Transactions Trends


DateBuySell
2025 Q4--
2025 Q3--
2025 Q2--

TVRD Ownership FAQ


Who Owns Tvardi Therapeutics?

Tvardi Therapeutics shareholders are primarily institutional investors at 19.53%, followed by 27.53% insiders and 52.94% retail investors. The average institutional ownership in Tvardi Therapeutics's industry, Biotech Stocks , is 379.48%, which Tvardi Therapeutics falls below.

Who owns the most shares of Tvardi Therapeutics?

Tvardi Therapeutics’s largest shareholders are Slate path capital lp (704.12K shares, 9.49%), Blackrock funding, inc. /de (388.08K shares, 5.23%), and Vanguard group (424.82K shares, 4.53%). Together, they hold 19.25% of Tvardi Therapeutics’s total shares outstanding.

Does Blackrock own Tvardi Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Tvardi Therapeutics.

Who is Tvardi Therapeutics’s biggest shareholder by percentage of total assets invested?

683 capital management is Tvardi Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.35% of its assets in 176.03K Tvardi Therapeutics shares, valued at 6.77M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools